Base de dados : LILACS
Pesquisa : D06.472.699.322.576.288 [Categoria DeCS]
Referências encontradas : 278 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 28 ir para página                         

  1 / 278 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-782851
Autor: Yamaçake, K. G. R; Cocuzza, M; Torricelli, F. C. M; Tiseo, B. C; Frati, R; Freire, G. C; Antunes, A. A; Srougi, M.
Título: Impact of body mass index, age and varicocele on reproductive hormone profile from elderly men
Fonte: Int. braz. j. urol;42(2):365-372, Mar.-Apr. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objectives: To study the impact of obesity, age and varicocele on sexual hormones fof adult and elderly men. Materials and Methods: 875 men who were screened for prostate cancer were enrolled in this study. Data recorded comprised age, body mass index (BMI), serum levels of total testosterone (TT), free testosterone (FT), sex hormone-binding globulin (SHBG), luteinizing hormone (LH) and follicular stimulating hormone (FSH). Patients were divided in groups according to their BMI in underweight, normal weight, overweight and obese grades 1, 2 or 3. First, it was studied the association between age, BMI, and hormone profile. Then, clinical varicocele was evaluated in 298 patients to assess its correlation to the others parameters. Results: Obese patients had lower levels of TT, FT and SHBG (p<0.001) compared to underweight or normal weight patients. There were no differences in age (p=0.113), FSH serum levels (p=0.863) and LH serum levels (p=0.218) between obese and non-obese patients. Obese grade 3 had lower levels of TT and FT compared to obese grade 1 and 2 (p<0.05). There was no difference in the SHBG levels (p=0.120) among obese patients. There was no association between varicocele and BMI; and varicocele did not impact on testosterone or SHBG levels. Conclusions: Men with higher BMI have a lower serum level of TT, FT and SHBG. The presence of clinical varicocele as well as its grade has no impact on hormone profile in elderly men.
Descritores: Testosterona/sangue
Varicocele/sangue
Globulina de Ligação a Hormônio Sexual/análise
Hormônio Luteinizante/sangue
Hormônio Foliculoestimulante/sangue
Obesidade/sangue
-Valores de Referência
Varicocele/fisiopatologia
Índice de Gravidade de Doença
Índice de Massa Corporal
Estudos Transversais
Fatores Etários
Estatísticas não Paramétricas
Pessoa de Meia-Idade
Obesidade/fisiopatologia
Limites: Humanos
Masculino
Idoso
Idoso de 80 Anos ou mais
Responsável: BR1.1 - BIREME


  2 / 278 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-828942
Autor: Marconi, Marcelo; Souper, Renato; Hartmann, Jonathan; Alvarez, Matías; Fuentes, Ignacio; Guarda, Francisco J.
Título: Clomiphene citrate treatment for late onset hypogonadism: rise and fall
Fonte: Int. braz. j. urol;42(6):1190-1194, Nov.-Dec. 2016. graf.
Idioma: en.
Resumo: ABSTRACT Objective: Previous series have demonstrated that Clomiphene Citrate (CC) is an effective treatment to increase Total Testosterone (TT) in Late Onset Hypogonadism (LOH) patients. However, what happens to TT levels after ending CC treatment is still debatable. The objective of this study is to evaluate TT levels 3 months after the discontinuation of CC in patients with LOH who were previously successfully treated with the same drug. Materials and Methods: Twenty-seven patients with LOH that were successfully treated (achieved TT levels >11nmol/l) with CC 50mgs daily for 50 days were prospectively recruited in our Andrological outpatient clinic. CC was then stopped for 3 months and TT levels were measured at the end of this period. Results: Mean TT level before discontinuation of CC was 22.7±8.1nmol/L (mean±SD). Three months after discontinuation, mean TT level significantly decreased in all patients, 10.2±3.9nmol/l (p<0.01). Twenty-one patients (78%) decreased TT levels under 11nmol/L. Six patients (22%) had TT levels that remained within the normal recommended range (≥11nmol/l). No statistical significant differences were observed between both groups. Conclusion: In the short term LOH does not seem to be a reversible condition in most patients after CC treatment. More studies with longer follow-up are needed to evaluate the kinetics of TT in LOH.
Descritores: Testosterona/sangue
Clomifeno/uso terapêutico
Antagonistas de Estrogênios/uso terapêutico
Hipogonadismo/terapia
-Hormônio Luteinizante/sangue
Estudos Prospectivos
Seguimentos
Resultado do Tratamento
Clomifeno/administração & dosagem
Antagonistas de Estrogênios/administração & dosagem
Hormônio Foliculoestimulante/sangue
Hipogonadismo/cirurgia
Pessoa de Meia-Idade
Limites: Humanos
Adulto
Idoso
Responsável: BR1.1 - BIREME


  3 / 278 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Mendonça, Berenice Bilharinho de
Texto completo
Id: biblio-890760
Autor: Cunha, Flávia Siqueira; Domenice, Sorahia; Sircili, Maria Helena Palma; Mendonca, Berenice Bilharinho de; Costa, Elaine Maria Frade.
Título: Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women
Fonte: Clinics;73:e86, 2018. tab.
Idioma: en.
Projeto: CNPq; . CNPq.
Resumo: OBJECTIVE: The ideal dosage of cross-sex hormones remains unknown. The aim of this study was to evaluate the luteinizing hormone, follicle-stimulating hormone, testosterone, estradiol and prolactin levels after low-dose estrogen therapy with or without cyproterone acetate in transgender women. METHODS: The serum hormone and biochemical profiles of 51 transgender women were evaluated before gonadectomy. Hormone therapy consisted of conjugated equine estrogen alone or combined with cyproterone acetate. The daily dose of conjugated equine estrogen was 0.625 mg in 41 subjects and 1.25 mg in 10 subjects, and the daily dose of cyproterone acetate was 50 mg in 42 subjects and 100 mg in one subject. RESULTS: Estrogen-only therapy reduced the testosterone, luteinizing hormone and follicle-stimulating hormone levels from 731.5 to 18 ng/dL, 6.3 to 1.1 U/L and 9.6 to 1.5 U/L, respectively. Estrogen plus cyproterone acetate reduced the testosterone, luteinizing hormone and follicle-stimulating hormone levels from 750 to 21 ng/dL, 6.8 to 0.6 U/L and 10 to 1.0 U/L, respectively. The serum levels of luteinizing hormone, follicle-stimulating hormone, testosterone, estradiol and prolactin in the patients treated with estrogen alone and estrogen plus cyproterone acetate were not significantly different. The group receiving estrogen plus cyproterone acetate had significantly higher levels of gamma-glutamyltransferase than the group receiving estrogen alone. No significant differences in the other biochemical parameters were evident between the patients receiving estrogen alone and estrogen plus cyproterone acetate. CONCLUSION: In our sample of transgender women, lower estrogen doses than those usually prescribed for these subjects were able to adjust the testosterone and estradiol levels to the physiological female range, thus avoiding high estrogen doses and their multiple associated side effects.
Descritores: Testosterona/sangue
Acetato de Ciproterona/administração & dosagem
Estradiol/sangue
Estrogênios/administração & dosagem
Pessoas Transgênero
Antagonistas de Androgênios/administração & dosagem
-Prolactina/sangue
Hormônio Luteinizante/sangue
Estudos Retrospectivos
Relação Dose-Resposta a Droga
Interações Medicamentosas
Estrogênios/sangue
Hormônio Foliculoestimulante/sangue
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Adulto Jovem
Tipo de Publ: Research Support, Non-U.S. Gov't
Ensaio Clínico
Responsável: BR1.1 - BIREME


  4 / 278 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-989971
Autor: Yoshimura, Koji; Nakashima, Yoshiharu; Sugiyama, Kyohei; Kohei, Naoki; Takizawa, Akitoshi.
Título: Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapy
Fonte: Int. braz. j. urol;45(1):38-44, Jan.-Feb. 2019. tab, graf.
Idioma: en.
Resumo: ABSTRACT Introduction: The main cause of slightly elevated human chorionic gonadotropin (HCG) after successful treatment of male germ cell tumors is considered to be pituitary-derived HCG. It is well known that pituitary-derived HCG is frequently detected in postmenopausal women. We evaluated the status of serum HCG in men with elevated gonadotropins, which were induced by androgen deprivation therapy, using commercially available assays. Materials and Methods: We enrolled 44 patients with prostate cancer, who underwent luteinizing-hormone releasing hormone agonist treatment. We measured serum follicle-stimulating hormone (FSH), serum luteinizing hormone (LH), serum total HCG, serum free HCG-β subunit, and urine total HCG 3 times per patient, on the day of treatment initiation, the next day, and 3 months after. Results: On the day after treatment initiation, serum and urine HCG was detected in 61% and 73% of patients, respectively. Markedly strong correlations were observed between serum/urine HCG and FSH/LH. In particular, receiver operating characteristic curve analysis indicated excellent area under the curve (0.977, 95% confidence interval 0.951-1.003)) for serum HCG-detectable LH. At the cutoff value of 21.07 mIU/mL for serum HCG-detectable LH, the sensitivity and specificity were 96.7% and 95.3%, respectively. Serum HCG-β was not detectable at any times in any patients. Conclusions: Suggested pituitary-derived HCG can be frequently detected in patients with elevated gonadotropins, and there is a firm association between HCG detection and gonadotropin levels.
Descritores: Neoplasias da Próstata/sangue
Testosterona/sangue
Hormônio Luteinizante/sangue
Hormônio Foliculoestimulante/sangue
Gonadotropina Coriônica/biossíntese
Gonadotropina Coriônica/sangue
-Neoplasias da Próstata/tratamento farmacológico
Curva ROC
Sensibilidade e Especificidade
Gonadotropina Coriônica Humana Subunidade beta/urina
Gonadotropina Coriônica Humana Subunidade beta/sangue
Antagonistas de Androgênios/administração & dosagem
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Adulto
Idoso
Idoso de 80 Anos ou mais
Tipo de Publ: Estudo Comparativo
Responsável: BR1.1 - BIREME


  5 / 278 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1040070
Autor: Haghmorad, Dariush; Mahmoudi, Mohammad Bagher; Haghighi, Pardis; Alidadiani, Paria; Shahvazian, Ensieh; Tavasolian, Parsova; Hosseini, Mahmoud; Mahmoudi, Mahmoud.
Título: Improvement of fertility parameters with tribulus terrestris and anacyclus pyrethrum treatment in male rats
Fonte: Int. braz. j. urol;45(5):1043-1054, Sept.-Dec. 2019. tab, graf.
Idioma: en.
Projeto: Mashhad University of Medical Sciences.
Resumo: ABSTRACT Objective Anacyclus Pyrethrum (AP) and Tribulus Terrestris (TT) have been reported as male infertility treatment in several studies; however, in Iranian traditional medicine these two plants are prescribed simultaneously. In this study, we aimed to determine the effects of AP and TT extracts both separately and simultaneously on the male Wistar rat fertility parameters. Materials and Methods 32 male Wistar rats were divided into 4 groups: Control, TT, AP, and AT treated groups. Treatment continued for 25 days and rats were weighed daily. Their testes were dissected for histological studies. Sperm analysis including sperm count, viability and motility were performed. Serum was obtained to evaluate testosterone, LH and FSH levels. Histological studies were conducted to study Leydig, and Sertoli cells, spermatogonia and spermatid cell numbers, and to measure seminiferous diameter and epithelium thickness. Results Sperm count increased in all the treatment groups. Sperm viability and motility in AT and AP groups were elevated. TT and AT groups showed significantly increased testosterone level compared to control group (P=004, P=0.000, respectively) and TT, AP and AT treatment groups showed increased LH level (P=0.002, P=0.03 and P=0.000, respectively) compared to control, while only AT group showed increased FSH (p=0.006) compared to control. Histological studies showed significant increase of spermatogonia, Leydig and Sertoli cell numbers and epithelial thickness in AT group compared to other groups. All the treatment groups had higher number of Leydig, spermatogonia and spermatid cells. Conclusion TT and AP improved sexual parameters; however, their simultaneous administration had higher improving effects on studied parameters.
Descritores: Chrysanthemum cinerariifolium/química
Extratos Vegetais/uso terapêutico
Tribulus/química
Infertilidade Masculina/tratamento farmacológico
-Tamanho do Órgão
Valores de Referência
Contagem de Espermatozoides
Motilidade Espermática/efeitos dos fármacos
Espermatozoides/efeitos dos fármacos
Testículo/efeitos dos fármacos
Testosterona/sangue
Peso Corporal
Hormônio Luteinizante/sangue
Extratos Vegetais/farmacologia
Reprodutibilidade dos Testes
Resultado do Tratamento
Ratos Wistar
Fertilidade/efeitos dos fármacos
Hormônio Foliculoestimulante/sangue
Limites: Humanos
Animais
Masculino
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  6 / 278 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Borges, Maria de Fátima
Texto completo
Id: biblio-1039542
Autor: Fujita, Lívia Grimaldi Abud; Palhares, Heloísa Marcelina da Cunha; da Silva, Adriana Paula; Tomé, Janaíne Machado; Borges, Maria de Fátima.
Título: Clinical and laboratory parameters of gonadotropin-releasing hormone analog treatment effectiveness in children with precocious puberty
Fonte: Clinics;74:e1205, 2019. tab, graf.
Idioma: en.
Resumo: OBJECTIVE: There are no doubts about the clinical benefits of treatment with GnRH analogs for patients diagnosed with central precocious puberty (CPP). However, laboratory monitoring of CPP is still a matter of considerable controversy in the literature. Therefore, the main objective of this study was to evaluate the cut-off values of stimulated LH that determine gonadotrophic suppression. METHODS: Twenty-four girls, on treatment with leuprorelin acetate (LA) at 3.75 mg IM every 28 days, were studied. The clinical parameters used to indicate clinical effectiveness were regression or maintenance of sexual characteristics according to the Tanner stage, growth velocity reduction, reduction or maintenance of the difference between bone age and chronological age and maintenance or improvement of the final height prediction. For the laboratory effectiveness test, basal estradiol, LH, and FSH levels were collected before and 1 and 2 h after the administration of 3.75 mg LA. RESULTS: Eleven girls showed improvement in all clinical parameters, and their effectiveness tests were compared to those of the other patients to calculate the cut-off values, which were ≤3.64 IU/L (p=0.004*) for LH after 1 h and ≤6.10 IU/L (p<0.001*) for LH after 2 h. CONCLUSION: The LH response after the LA stimulation test, associated with clinical data and within a context of CPP, constitutes a reliable and feasible resource and can assist in monitoring the effectiveness of treatment.
Descritores: Puberdade Precoce/tratamento farmacológico
Hormônio Liberador de Gonadotropina/uso terapêutico
Leuprolida/uso terapêutico
Hormônio Foliculoestimulante/sangue
-Puberdade Precoce/sangue
Estudos de Casos e Controles
Hormônio Liberador de Gonadotropina/análogos & derivados
Resultado do Tratamento
Limites: Humanos
Masculino
Feminino
Criança
Responsável: BR1.1 - BIREME


  7 / 278 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1046915
Autor: Moraes, Mayara Ellen Bardi de; Adona, Paulo Roberto; Guemra, Samuel; Bem, Tiago Henrique Camara de; Miranda, Moysés dos Santos.
Título: Effect of single dose follicle stimulating hormone on follicular aspiration, in vitro fertilization and pregnancy rate / Efeito do hormônio folículo estimulante em dose única na aspiração folicular, fertilização in vitro e taxa de prenhez
Fonte: Braz. J. Vet. Res. Anim. Sci. (Online);56(3):e156894, out. 2019. tab, ilus.
Idioma: en.
Resumo: The present study evaluated Brangus cows treated with single doses of follicle stimulating hormone (FSH) subjected to follicular aspiration after 24 h to assess oocyte recovery, in vitro fertilization and pregnancy rate. Follicles exceeding 3 millimeters in diameter were aspirated, 200 mg of FSH was administered 2 days later, and a new ovum pickup was performed 24 h afterward. These methods were performed 3 times every 3 days. In control, follicular aspirations occurred at intervals of 1-week without FSH administration o. The aspirated oocytes were evaluated, submitted to in v itrofertilization and the embryos were transferred to the recipients. The average recovery of oocytes was higher (p<0.05) in control cows (12.4±1.8) than in treated cows (9.4±1.3). There was no difference (p>0.05) in the mean percentage of viable oocytes (52.0±3.9 and 62.7±4.7%) or the mean percentage of embryos (41.4±4.8 and 41.5±4.2%) among control and treated cows, respectively. The mean percentage of pregnancy did not differ (p>0.05) for control cows (43.8±2.7%), and treated cows (40.9±6.8%). In conclusion, FSH treatment did not improve oocyte recovery, in vitro fertilization, and pregnancy percentage. However, there is possibility of several consecutive ovum pickup every t3 days, concentrating the in vitro fertilization and the pregnancy percentage.

O presente estudo avaliou vacas Brangus tratadas com doses únicas de hormônio folículo estimulante (FSH) submetidas a aspiração folicular após vinte e quatro horas, para avaliação da recuperação oocitária, fertilização in vitro e taxa de prenhez. Folículos superiores a três milímetros de diâmetro foram aspirados, 200 mg de FSH foram administrados dois dias depois e uma nova aspiração folicular foi realizada 24 horas após. Esses métodos foram efetivados três vezes a cada três dias. No controle, as aspirações foliculares ocorreram em intervalos de uma semana sem administração de FSH. Os oócitos aspirados foram avaliados, submetidos à fertilização in vitro e os embriões foram transferidos em receptoras. A recuperação média dos oócitos foi superior (p<0,05) nas vacas controle (12,4±1,8) do que nas vacas tratadas (9,4±1,3). Não houve diferença (p>0,05) na porcentagem média de oócitos viáveis (52,0±3,9 e 62,7±4,7%) ou na porcentagem média de embriões (41,4±4,8 e 41,5±4,2%) entre vacas controle e vacas tratadas, respectivamente. A porcentagem média de prenhez não diferiu (p>0,05) para as vacas controle (43,8±2,7%) e as tratadas (40,9±6,8%). Em conclusão, o tratamento com FSH não melhorou a recuperação de oócitos, a fertilização in vitro e o percentual de prenhez. No entanto, existe a possibilidade de várias aspirações foliculares consecutivas a cada três dias, concentrando a fertilização in vitro e o percentual de prenhez.
Descritores: Prenhez/imunologia
Bovinos/metabolismo
Fertilização In Vitro/estatística & dados numéricos
-Hormônio Foliculoestimulante/efeitos adversos
Limites: Animais
Feminino
Bovinos
Responsável: BR68.1 - Biblioteca Virginie Buff D'Ápice


  8 / 278 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-887572
Autor: Diniz, Tiego A; Rossi, Fabricio E; Silveira, Loreana S; Neves, Lucas Melo; Fortaleza, Ana Claudia de Souza; Christofaro, Diego G D; Lira, Fabio S; Freitas-Junior, Ismael F.
Título: The role of moderate-to-vigorous physical activity in mediating the relationship between central adiposity and immunometabolic profile in postmenopausal women
Fonte: Arch. endocrinol. metab. (Online);61(4):354-360, July-Aug. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objectives To analyze the role of moderate-to-vigorous physical activity (MVPA) in mediating the relationship between central adiposity and immune and metabolic profile in postmenopausal women. Materials and methods Cross-sectional study comprising 49 postmenopausal women (aged 59.26 ± 8.32 years) without regular physical exercise practice. Body composition was measured by dual-energy X-ray absorptiometry. Fasting blood samples were collected for assessment of nonesterified fatty acids, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), adiponectin, insulin and estimation of insulin resistance (HOMA-IR). Physical activity level was assessed with an accelerometer (Actigraph GTX3x) and reported as a percentage of time spent in sedentary behavior and MVPA. All analyses were performed using the software SPSS 17.0, with a significance level set at 5%. Results Sedentary women had a positive relationship between trunk fat and IL-6 (rho = 0.471; p = 0.020), and trunk fat and HOMA-IR (rho = 0.418; p = 0.042). Adiponectin and fat mass (%) were only positively correlated in physically active women (rho = 0.441; p = 0.027). Physically active women with normal trunk fat values presented a 14.7% lower chance of having increased HOMA-IR levels (β [95%CI] = 0.147 [0.027; 0.811]). Conclusions The practice of sufficient levels of MVPA was a protective factor against immunometabolic disorders in postmenopausal women.
Descritores: Exercício Físico
Interleucina-6/sangue
Pós-Menopausa/metabolismo
Obesidade Abdominal/sangue
-Composição Corporal
Resistência à Insulina
Absorciometria de Fóton/instrumentação
Estudos Transversais
Jejum/sangue
Pós-Menopausa/sangue
Gordura Abdominal/metabolismo
Adiponectina/sangue
Adiposidade
Ácidos Graxos/sangue
Comportamento Sedentário
Fatores de Proteção
Hormônio Foliculoestimulante/sangue
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Idoso
Responsável: BR1.1 - BIREME


  9 / 278 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-553332
Autor: Rizzo, Maria de Fátima Valente.
Título: Avaliação da disfunção gonadal em pacientes do sexo masculino, submetidos a tratamento oncológico na infância / Evaluation of the male gonadal function submitted to treatment in the childhood cancer.
Fonte: São Paulo; s.n; 2008. 88 p. ilus, tab.
Idioma: pt.
Tese: Apresentada a Fundação Antônio Prudente para obtenção do grau de Doutor.
Resumo: INTRODUÇÃO: À medida que aumenta o número de adultos que sobrevivem ao tratamento do câncer infantil, observa-se a presença de efeitos tardios decorrentes do tratamento. ... OBJETIVO: Avaliar a função gonadal nos pacientes submetidos a diferentes esquemas de tratamento na infância e identificar os fatores de risco para disfunção gonadal neste grupo. CASUÍSTICA E MÉTODOS: Foram avaliados 151 pacientes, que fazem parte do GEPETTO (Grupo de Estudos Pediátricos dos Efeitos Tardios do Tratamento Oncológico) fora de tratamento há mais de 8 anos, que deram entrada no Hospital A.C. Camargo entre 1966 a 1994. ... RESULTADOS: Azoospermia foi observada em 43 pacientes. As dosagens séricas mostraram 36 pacientes com FSH alterada, 26 pacientes com testosterona total anormal e 18 pacientes com LH alterado. ... O estudo da regressão logística observou que a procarbazina (OR=7,7 para o grupo B e 10,3 para o grupo A), etoposide (OR=3,9 para o grupo A), doxorrubicina (OR=1,9 para o grupo C) e a Rxt testicular (OR=38 para o grupo C), tiveram impacto na disfunção gonadal. CONCLUSÕES: Os pacientes tratados na infância com regimes combinados de quimioterapia e/ou radioterapia apresentaram evidências de dano gonadal, com a presença de FSH alterado e/ou azoospermia e/ou volume testicular diminuído, sugerindo importante dano ao epitélio germinativo...

INTRODUCTION: As far as a majority of children with malignant diseases are cured, the late effects of the treatment are of major importance. The gonadal dysfunction is one of the undesirable late effects due to the treatment. OBJECTIVES: To evaluate the male gonadal function, submitted to treatment in the childhood and to identify the risk factors for gonadal dysfunction in this group. PATIENTS AND METHODS: Semen quality, hormonal status and testicular volume were evaluated in 151 patients treated from 1966 to 1994 in the A.C. Camargo Hospital. The age at diagnosis varied from 0.3 to 18.6 years old, with medium age 6.9 years; 114 (75.50%) patients were prepubertal (< 10 years) and 37 (24.50%) were pubertal. They were revaluated after a long period off (median of 14 years). The patients were separed in groups: group A (alterations at least in a variable: FSH, LH, testosterone, testicular volume and azoospermia), group B (increased FSH values and/or azoospermia) and group C (increased LH and/or testosterone values). RESULTS: Azoospermia was observed in 43 patients. Serum levels showed 36 patients with increased FSH values, 26 patients with abnormal total testosterone and 18 patient with increased LH values The testicular radiation was significant in three groups when compared the normal patients results versus abnormal ones (p<0.001). Nitrogen mustard and especially procarbazine were highly significant in group A and B (p<0.001),and daunorubicin (p<0.001) in group C. Logistic regression was observed that procarbazina showed the OR=7.7 for group B and OR= 10.3 for group A), etoposide (OR=3.9 for group A), doxorrubicina (OR=1.9 for group C), and testicular radiation (OR=38 for group C), were associated with impact in the gonadal dysfunction. CONCLUSIONS: The patients treated in the childhood with combined chemotherapy and/or radiotherapy presented evidences of gonadal, damage with increased FSH and/or azoospermia and/or reduction of testicular size, suggesting important damage to the germinal epithelium.
Descritores: Hormônio Foliculoestimulante
Azoospermia
Neoplasias Testiculares
Testosterona
Testículo
Testículo
-Hormônio Luteinizante
Tratamento Farmacológico
Radioterapia
Limites: Masculino
Criança
Responsável: BR30.1 - Biblioteca
BR30.1


  10 / 278 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1088773
Autor: Cardoso, Nathália Sigilló; Ribeiro, Victor Barbosa; Dutra, Sabrina Graziani Veloso; Ferriani, Rui Alberto; Gastaldi, Ada Clarice; Araújo, João Eduardo de; Souza, Hugo Celso Dutra de.
Título: Polycystic ovary syndrome associated with increased adiposity interferes with serum levels of TNF-alpha and IL-6 differently from leptin and adiponectin
Fonte: Arch. endocrinol. metab. (Online);64(1):4-10, Jan.-Feb. 2020. tab.
Idioma: en.
Projeto: Fapesp.
Resumo: ABSTRACT Objective The aim of this study was to investigate polycystic ovary syndrome (PCOS) and to explore the relationship between body fat percentage and metabolic markers. Subjects and methods Sedentary women were assigned to PCOS (N = 60) and CONTROL (N = 60) groups. Each group was subdivided into three subgroups according to body fat percentage (22-27%, 27-32% and 32-37%). The protocol consisted of assessments of glucose, insulin, androgens, follicle stimulating hormone (FSH), luteinizing hormone (LH), 17-hydroxyprogesterone (17-OHP), leptin, adiponectin, tumor necrosis factor (TNF-α) and interleukin-6 (IL-6). Results The PCOS subgroups showed higher concentrations of androgens, LH and 17-OHP. Leptin showed direct relationship with increased body fat percentage, whereas adiponectin showed the inverse effect. However, both were unaffected by PCOS. TNF-α and IL-6 were higher in PCOS women and showed a direct relationship with increased body fat percentage. Glucose showed direct relationship with body fat percentage, whereas insulin presented higher values in PCOS women and direct relationship with increased body fat percentage. Conclusions Our findings indicate that PCOS and body fat percentage directly influence concentrations of insulin, TNF-α and IL-6, whereas leptin and adiponectin are influenced only by the increase in body fat percentage in these women. Arch Endocrinol Metab. 2020;64(1):4-10
Descritores: Biomarcadores/sangue
Tecido Adiposo/anatomia & histologia
Doenças Metabólicas/sangue
-Resistência à Insulina
Hormônio Luteinizante/sangue
Índice de Massa Corporal
Estudos de Casos e Controles
Interleucina-6/sangue
Fator de Necrose Tumoral alfa/sangue
17-alfa-Hidroxiprogesterona/sangue
Leptina/sangue
Adiponectina/sangue
Hormônio Foliculoestimulante/sangue
Glucose/análise
Androgênios/sangue
Insulina/sangue
Limites: Humanos
Feminino
Adolescente
Adulto
Adulto Jovem
Responsável: BR1.1 - BIREME



página 1 de 28 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde